TY - JOUR T1 - Microvascular endothelial dysfunction in heart failure with preserved ejection fraction JF - Heart JO - Heart SP - 257 LP - 259 DO - 10.1136/heartjnl-2015-308852 VL - 102 IS - 4 AU - Carolyn S P Lam AU - Lars H Lund Y1 - 2016/02/15 UR - http://heart.bmj.com/content/102/4/257.abstract N2 - A new paradigm has emerged in our understanding of the pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF). Comorbidity-driven cardiac endothelial dysfunction plays a primary role in HFpEF, leading to cardiomyocyte dysfunction, left ventricular (LV) concentric remodelling and predominantly diastolic dysfunction1 (figure 1). Conversely in HFrEF, direct cardiomyocyte injury is the key trigger for systemic neuroendocrine activation, LV eccentric remodelling and predominantly systolic dysfunction.1 Whereas neuroendocrine activation exists as a common defining domain of the HF syndrome in both HFrEF and HFpEF, in HFrEF it plays a dominant role in adverse remodelling and outcomes; thus antagonists of the renin-angiotensin-aldosterone and adrenergic systems have been effective in improving survival in HFrEF. Similarly, whereas cardiovascular endothelial dysfunction exists in both HFpEF and HFrEF, by the new paradigm, it is postulated to play a dominant role in the pathophysiology and outcomes of HFpEF. This distinction is critical since targeting endothelial dysfunction may be a winning strategy in HFpEF—a condition now recognised as one of the largest unmet needs in cardiovascular medicine, responsible for half the HF epidemic and without proven therapies to improve survival.2Figure 1 Heart failure with preserved ejection fraction (HFpEF) paradigm. In HFpEF, comorbidities (such as hypertension, overweight, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, anaemia and iron deficiency) lead to microvascular inflammation and endothelial activation. This adversely affects the adjacent cardiomyocyte through decreased nitric oxide (NO) bioavailability, reduced cyclic guanosine monophosphate (cGMP) availability, and altered phosphorylation of titin; microvascular ischaemia, concentric left ventricular (LV) remodelling and fibrosis from endothelial-mesenchymal transition (EndMT) contributes further to LV diastolic dysfunction. In contrast, in … ER -